AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15333734 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) with high isoflavone content (mean intake 96 mg/d)
Number of subjects: 8
Study 15333734 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate (SPI) with low isoflavone content (mean intake 6 mg/d)
Number of subjects: 8
Study 15333734 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone intake in hypercholesterolemic subjects
Number of subjects: 8
Study 15333734 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone intake in normocholesterolemic subjects
Number of subjects: 8
Study 11441210 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced (CI) aphasia therapy
Number of subjects: 17
Study 11441210 — intervention group
Group type: COMPARATOR
Intervention: Conventional aphasia therapy
Number of subjects: 17
Study 9459258 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg
Number of subjects: 61
Study 9459258 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 microg/kg
Number of subjects: 61
Study 9459258 — intervention group
Group type: COMPARATOR
Intervention: Control (0 microg/kg)
Number of subjects: 61
Study 7972189 — intervention group
Group type: EXPERIMENTAL
Intervention: New dressing for digit injuries
Number of subjects: 0
Study 7972189 — intervention group
Group type: COMPARATOR
Intervention: Traditional digit dressings
Number of subjects: 0
Study 2541985 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (6.6 g/bar, average consumption 31.7 g/day)
Number of subjects: 16
Study 2541985 — intervention group
Group type: COMPARATOR
Intervention: Placebo bar (no guar gum)
Number of subjects: 16
Study 31691181 — intervention group
Group type: EXPERIMENTAL
Intervention: Social ties (affective, personal, and professional ties) rated on a 5-point Likert scale
Number of subjects: 272
Study 31691181 — intervention group
Group type: COMPARATOR
Intervention: Clinical experience, demographics, and knowledge of team roles
Number of subjects: 272
Study 28340136 — intervention group
Group type: EXPERIMENTAL
Intervention: TAJ-Plus (with added class smoke-free pledge)
Number of subjects: 433
Study 28340136 — intervention group
Group type: COMPARATOR
Intervention: TAJ (Triple A in Jordan)
Number of subjects: 433
Study 26356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8-week supervised program of endurance and resistance exercise)
Number of subjects: 188
Study 26356698 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 188
Study 26356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 188
Study 26356698 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 23930712 — intervention group
Group type: COMPARATOR
Intervention: Diet A (control) - 6.4g lysine per 100g CP
Number of subjects: 432
Study 23930712 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B - 4.5g lysine per 100g CP
Number of subjects: 432
Study 23930712 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B
Number of subjects: 432
Study 23930712 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A
Number of subjects: 432
Study 21118735 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 20 mg BID (group A)
Number of subjects: 184
Study 21118735 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 40 mg BID (group B)
Number of subjects: 184
Study 21118735 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Rabeprazole 10 mg BID (group C)
Number of subjects: 184
Study 21118735 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype effect on eradication rates
Number of subjects: 184
Study 21118735 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 184
Study 18230244 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin (MFX)
Number of subjects: 217
Study 18230244 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin (GFX)
Number of subjects: 217
Study 18230244 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin (OFX)
Number of subjects: 217
Study 18230244 — intervention group
Group type: COMPARATOR
Intervention: isoniazid (INH), pyrazinamide and rifampicin (RMP) with either ethambutol, GFX, MFX or OFX
Number of subjects: 217
Study 16368293 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5 mg once a week, n = 35)
Number of subjects: 71
Study 15753186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil plus different doses of vitamin E for 3 months
Number of subjects: 0
Study 10992331 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐ORS (245 mmol/liter)
Number of subjects: 170
Study 9030787 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt dissection
Number of subjects: 32
Study 9030787 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic en-bloc resection (EB)
Number of subjects: 32
Study 8130297 — intervention group
Group type: EXPERIMENTAL
Intervention: R (simple relaxation)
Number of subjects: 117
Study 8130297 — intervention group
Group type: EXPERIMENTAL
Intervention: REMG (R + EMG biofeedback)
Number of subjects: 117
Study 8130297 — intervention group
Group type: EXPERIMENTAL
Intervention: BP (BP biofeedback only)
Number of subjects: 117
Study 8130297 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP (R + BP)
Number of subjects: 117
Study 8130297 — intervention group
Group type: COMPARATOR
Intervention: Control Group (TA, reading about transactional analysis without skills training)
Number of subjects: 117
Study 3773599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine
Number of subjects: 43
Study 3773599 — intervention group
Group type: COMPARATOR
Intervention: Combination of dipyrone, pitofenone and fenpipramide (control)
Number of subjects: 43
Study 3773599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 43
Study 29516425 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid (2%) and recombinant human interferon after ALA-PDT
Number of subjects: 718
Study 29516425 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human interferon (control group)
Number of subjects: 718
Study 29516425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid group (for PDT-associated infection)
Number of subjects: 718
Study 29516425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin group (for PDT-associated infection)
Number of subjects: 718
Study 27404516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 59
Study 27404516 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO)
Number of subjects: 59
Study 27404516 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (CO)
Number of subjects: 59
Study 24944063 — intervention group
Group type: COMPARATOR
Intervention: 0 egg yolks
Number of subjects: 6
Study 24944063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg yolk
Number of subjects: 6
Study 24944063 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 egg yolks
Number of subjects: 6
Study 24944063 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 egg yolks
Number of subjects: 6
Study 24944063 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 egg yolks
Number of subjects: 6
Study 22939358 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone combined with azilsartan medoxomil
Number of subjects: 609
Study 22939358 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide combined with azilsartan medoxomil
Number of subjects: 609
Study 20028948 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week combined progressive training program, 3 times per week, 45 min per session)
Number of subjects: 38
Study 19016941 — intervention group
Group type: EXPERIMENTAL
Intervention: BIMS (Brief Interview of Mental Status) administered by research assistants
Number of subjects: 374
Study 19016941 — intervention group
Group type: EXPERIMENTAL
Intervention: BIMS (Brief Interview of Mental Status) administered by facility nurses
Number of subjects: 374
Study 19016941 — intervention group
Group type: EXPERIMENTAL
Intervention: BIMS for any impairment (3MS<78)
Number of subjects: 374
Study 19016941 — intervention group
Group type: EXPERIMENTAL
Intervention: BIMS for severe impairment (3MS<48)
Number of subjects: 374
Study 16523022 — intervention group
Group type: EXPERIMENTAL
Intervention: iPAT with acceleration factor of 2
Number of subjects: 24
Study 16523022 — intervention group
Group type: COMPARATOR
Intervention: iPAT with acceleration factor of 4
Number of subjects: 24
Study 12778045 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-controlled feeding approach
Number of subjects: 0
Study 12778045 — intervention group
Group type: COMPARATOR
Intervention: Behavioral counseling studies
Number of subjects: 0
Study 12778045 — intervention group
Group type: EXPERIMENTAL
Intervention: Research diets prepared by dietitians
Number of subjects: 0
Study 12778045 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy requirement adjustments
Number of subjects: 0
Study 12778045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical treatment and motivation of participants
Number of subjects: 0
Study 11099449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients with central arm paresis
Number of subjects: 23
Study 11099449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients with somatosensory deficits
Number of subjects: 23
Study 11099449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients with ideomotor apraxia
Number of subjects: 23
Study 11099449 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study 8780817 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) therapy
Number of subjects: 46
Study 8780817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy (ZDV/ddI)
Number of subjects: 46
Study 8780817 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) therapy (monotherapy or alternating)
Number of subjects: 46
Study 1600993 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 150 mg daily for 4 weeks
Number of subjects: 20
Study 1600993 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 60 mg daily for 4 weeks
Number of subjects: 20
Study 1600993 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 6541198 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: rifampin 600 mg twice weekly, prothionamide 500 mg, and dapsone (DDS) 100 mg daily for six months, followed by 100 mg DDS daily for another six months
Number of subjects: 20
Study 6541198 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: identical to Regimen A but without prothionamide
Number of subjects: 20
Study 29710289 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisafe smartphone app
Number of subjects: 412
Study 29710289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 412
Study 27404902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bali Yoga Program for Breast Cancer Patients (BYP‐BC)
Number of subjects: 101
Study 27404902 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (standard care)
Number of subjects: 101
Study 27404902 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 101
Study 24793093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine (IV BUP)
Number of subjects: 25
Study 24793093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (IN BUP)
Number of subjects: 25
Study 24793093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22740213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Nutrition Assessment (MNA)
Number of subjects: 103
Study 22740213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Nutrition Assessment Short-Form (MNASF)
Number of subjects: 103
Study 22740213 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 103
Study 19680659 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 ml of low-density barium sulphate (LDB) (group C)
Number of subjects: 90
Study 19680659 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 ml of low-density barium sulphate (LDB) (groups C, D, E)
Number of subjects: 90
Study 19680659 — intervention group
Group type: COMPARATOR
Intervention: No oral contrast agent (group A)
Number of subjects: 90
Study 19680659 — intervention group
Group type: COMPARATOR
Intervention: 900 ml of water (group B)
Number of subjects: 90
Study 18559644 — intervention group
Group type: COMPARATOR
Intervention: 75 mg oral oseltamivir every 24 h (group 1)
Number of subjects: 48
Study 18559644 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oseltamivir every 48 h combined with 500 mg probenecid four times a day (group 2)
Number of subjects: 48
Study 18559644 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3)
Number of subjects: 48
Study 15984725 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form with 70 subitems
Number of subjects: 0
Study 15984725 — intervention group
Group type: COMPARATOR
Intervention: Long form with 140 subitems
Number of subjects: 0
Study 12215687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.2 mg/ml
Number of subjects: 83
Study 12215687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/ml
Number of subjects: 83
Study 12215687 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) 0.2 mg/ml and 0.4 mg/ml
Number of subjects: 83
Study 10667741 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 245
Study 10667741 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol or another conventional antipsychotic
Number of subjects: 245
Study 7541769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GH (0.125 IU/kg/week)
Number of subjects: 12
Study 7541769 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH (0.5 IU/kg/week)
Number of subjects: 12
Study 2116083 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg/day for 6 months)
Number of subjects: 111
Study 2116083 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medication group)
Number of subjects: 111
Study 877639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive foam containing a local anesthetic plus a corticosteroid
Number of subjects: 100
Study 877639 — intervention group
Group type: COMPARATOR
Intervention: Spray containing a local anesthetic plus an antiseptic agent
Number of subjects: 100
Study 31111123 — intervention group
Group type: EXPERIMENTAL
Intervention: InGaAsP followed by subgingival debridement (SD) and Er,Cr:YSGG laser
Number of subjects: 42
Study 31111123 — intervention group
Group type: COMPARATOR
Intervention: Subgingival debridement (SD) alone
Number of subjects: 42
Study 28333029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted hyaluronidase (8 IU/mL)
Number of subjects: 22
Study 28333029 — intervention group
Group type: COMPARATOR
Intervention: Normal hyaluronidase (80 IU/mL)
Number of subjects: 22
Study 25843912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of 5-aminolevulinic acid (5-ALA)
Number of subjects: 62
Study 25843912 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg of 5-aminolevulinic acid (5-ALA)
Number of subjects: 62
Study 25843912 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic diagnosis
Number of subjects: 62
Study 23816561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal chronomodulated infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Number of subjects: 124
Study 23816561 — intervention group
Group type: COMPARATOR
Intervention: Flat intermittent constant rate infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Number of subjects: 124
Study 21356150 — intervention group
Group type: EXPERIMENTAL
Intervention: Six servings of low glycaemic index (LGI) foods daily
Number of subjects: 35
Study 21356150 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight servings of low glycaemic index (LGI) foods daily
Number of subjects: 35
Study 19081704 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for physicians
Number of subjects: 0
Study 17405995 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard chemotherapy, 87% received cyclophosphamide, methotrexate, and 5-fluorouracil; 11% received anthracycline-containing regimens)
Number of subjects: 1991
Study 17405995 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard chemotherapy)
Number of subjects: 1991
Study 10821994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact order/original wording (n=148)
Number of subjects: 688
Study 10821994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact order/revised wording (n=183)
Number of subjects: 688
Study 10821994 — intervention group
Group type: EXPERIMENTAL
Intervention: Split order/original wording (n=192)
Number of subjects: 688
Study 10821994 — intervention group
Group type: EXPERIMENTAL
Intervention: Split order/revised wording (n=166)
Number of subjects: 688
Study 8787073 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug (specific drug not mentioned)
Number of subjects: 0
Study 8787073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1899746 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging with a body coil
Number of subjects: 26
Study 6131857 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 150 mg ranitidine
Number of subjects: 60
Study 6131857 — intervention group
Group type: COMPARATOR
Intervention: 2 x 400 mg cimetidine
Number of subjects: 60
Study 31067347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (screening with prostate-specific antigen and digital rectal examination)
Number of subjects: 76383
Study 31067347 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 76383
Study 29318868 — intervention group
Group type: EXPERIMENTAL
Intervention: medium renewed on day 3
Number of subjects: 82
Study 29318868 — intervention group
Group type: COMPARATOR
Intervention: medium not renewed on day 3
Number of subjects: 82
Study 27100364 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood negative emotionality (NE)
Number of subjects: 160
Study 27100364 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic alcohol use
Number of subjects: 160
Study 25146732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 0
Study 25146732 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency current (RFC) ablation
Number of subjects: 0
Study 22966034 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral techniques delivered over 1 to 3 individual nurse consultations at infant age 8 to 10 months
Number of subjects: 326
Study 22966034 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326
Study 19927136 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Number of subjects: 228
Study 19927136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill count
Number of subjects: 228
Study 19927136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MEMS and pill count
Number of subjects: 228
Study 19927136 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS
Number of subjects: 228
Study 19927136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 228
Study 17873682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation (LFR-TMS)
Number of subjects: 26
Study 17873682 — intervention group
Group type: COMPARATOR
Intervention: High-frequency left-sided transcranial magnetic stimulation (HFL-TMS)
Number of subjects: 26
Study 15957843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiyishu Injection (AYSI), 50 ml by intrathoracic and another 50 ml by intravenous injection, repeated after 3 days.
Number of subjects: 60
Study 15957843 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutic agent or interleukin-2 (IL-2)
Number of subjects: 60
Study 12048138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment for 3 months
Number of subjects: 853
Study 12048138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment
Number of subjects: 853
Study 9924649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 0
Study 7573262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride, 30 mg per day
Number of subjects: 342
Study 7573262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 2253535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times a day
Number of subjects: 80
Study 2253535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice a day
Number of subjects: 80
Study 2253535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times a day
Number of subjects: 80
Study 2253535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2253535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (both dosages)
Number of subjects: 80
Study 31219671 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact, cost-effective education program (CEPT1) - 3 sessions of 90 minutes each, with one session per week, containing five short videos.
Number of subjects: 62
Study 31219671 — intervention group
Group type: COMPARATOR
Intervention: Control group - extensive education program delivered through 45-minute PowerPoint lectures, one class every 3 months.
Number of subjects: 62
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 0.25 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 1 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 3 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 6 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 6 mg/kg (all three doses)
Number of subjects: 135
Study 29057618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135